GSK And Other Firms Look To Follow Moderna Into mRNA Flu Vaccine Space
Recent FDA nod for mFLUSIVA may have opened the door for other novel flu vaccine approaches. GSK is moving into Phase III, while Osivax and GC announced a T-cell program, one of an estimated 46 next-gen flu vaccine candidates advancing in the clinic.
Scrip - September 1, 2026

Trump Administration Signs Nine New MFN Deals, The First With Mid-Sized Firms
The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according to the White House, and agreements with companies representing the remainder are expected “very soon.”
Scrip - September 1, 2026

Boston Scientific Discontinues Imager II Catheter. FDA Issues Early Alert Over Detachment Risk
The FDA said Boston Scientific is removing its Imager II Angiographic Catheters because a manufacturing issue could cause the catheter tip to degrade and detach during use. The company has also decided to discontinue the device. Two serious injuries and no deaths are associated with the recall.
Medtech Insight - August 31, 2026

Philips Joins ARPA-H’s Autonomous Stroke Intervention Race With $33.7m Award
ARPA-H is funding four competing teams to solve the same problem — too few stroke specialists, too far from too many patients — and Philips' $33.7m award is the latest piece of a $175m bet on autonomous endovascular robotics.
Medtech Insight - August 31, 2026

MHRA Directs NHS To Review Cobalt-Chrome Modular-Neck Hip Implants From Five Makers
The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and Smith+Nephew found heightened wear, corrosion and tissue-reaction risks in about 750 patients. All affected implants had already been withdrawn from the market.
Medtech Insight - August 31, 2026

Herbalife Approaching Executive Suite Shift While Pivoting To Personalization Focus
Nutrition, health and wellness product direct seller says CEO Stephan Gratziani will leave on Oct. 31 while continuing as a strategy and business development consultant and CFO John DeSimone will serve as interim CEO before retiring at the end of the year.
HBW Insight - August 31, 2026

Global Regulators Align on Cosmetics E-Labeling
Cosmetic regulators from across the globe came together and agreed on general principles for minimizing barriers to trade at the meeting of the International Cooperation on Cosmetics Regulation this summer.
HBW Insight - August 31, 2026

FDA Consumer Health Advisory: Further OTC Regulatory Reform Needed
What's happening, why it matters and what's next at FDA. This edition explores the ongoing changes needed to OTC regulation flagged by CHPA's Scott Melville, a sizable eye drops recall, acetaminophen adverse events, and more.
HBW Insight - August 31, 2026

Rogaine Firm Kenvue’s Challenge Clips Ad Claims For Hims & Hers’ Compounded Hair Growth Drug
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026

Apotex Addresses Tariffs As US-Canada Tensions Rise
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026

Takeda Patent Suit Puts Early Entyvio Biosimilar Launches Under Pressure
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026

Mylan, Lannett Must Face Humana Jury On Generic Price-Fixing Claims
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026

Lupin Targets Bigger Global Role For Europe And Emerging Markets
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026

De-Risked Doesn’t Mean It’s A Safe Bet
Big pharma's late-stage M&A is not delivering: across deals since 2021, only 12 of the 33 involving a de-risked asset generated a multiple above 1.0x. In nearly two-thirds of cases the consensus forecast value of the late-stage assets acquired was less than the price paid for the company.
In Vivo - August 29, 2026